Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Public Health

Sec. Public Health Policy

Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1572558

Evaluation of the Disease Burden of Nosocomial Infection among Inpatients in a Cancer Hospital Based on Propensity Score Matching

Provisionally accepted
Jiayang  TangJiayang Tang1Jiang  YuanJiang Yuan2Hui  WangHui Wang1Qin  HuangQin Huang1Weiwei  YangWeiwei Yang1Qingqing  TianQingqing Tian1Anran  LiuAnran Liu1Hailin  ZhangHailin Zhang1Chunlin  WuChunlin Wu1*
  • 1Sichuan Clinical Research Center for Cancer,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China
  • 2School of Public Health, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China

The final, formatted version of the article will be published soon.

Oncology patients, as an immunocompromised population, are particularly susceptible to hospital-acquired infections (HAIs) . This study aims to establish a scientifically sound model to estimate the disease burden associated with HAIs in oncology patients, providing valuable decision-making support for healthcare systems and public health management.Propensity score matching (PSM) was employed. Post-matching permutation tests were applied to compare hospitalization costs and lengths of stay between the HAIs and non-HAI groups, as well as between the multidrug-resistant bacteria (MDRO) infection group and non-MDRO group.The results indicate that the average hospitalization cost in the HAIs group was 23.7% higher than the non-HAI groups, with a median difference of 12,417.6 CNY. Among various hospitalization expenses, the largest disparity was observed in the cost of Western medications, which had a median difference of 5,453.79 CNY, representing a 54.38% increase. The average length of hospital stay in the HAIs group was 1.33 times that of the control group. For the MDRO infection group, the average hospitalization cost exceeded that of the control group by 56.43%, with an absolute difference of 32,266.62 CNY. Additionally, the average length of hospital stay in the MDRO group was 42.11% longer, extending by 8 days.Both HAIs and MDRO infections significantly increase hospitalization duration and costs. The resulting disease burden is reflected in the direct escalation of health economic costs and the indirect effects of reduced hospital operational efficiency and heightened strain on the healthcare system. On this basis, we conclude that the funds for the prevention and control of HAIs and MDRO infections should be increased, and the measures for the prevention and control of HAIs should be implemented effectively, so as to reduce the direct and indirect economic burdens caused by HAIs and MDRO infections.

Keywords: Propensity score matching, Nosocomial infection, Multidrug-resistant bacterial infections, the Disease Burden, Oncology patients

Received: 07 Feb 2025; Accepted: 26 Jun 2025.

Copyright: © 2025 Tang, Yuan, Wang, Huang, Yang, Tian, Liu, Zhang and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Chunlin Wu, Sichuan Clinical Research Center for Cancer,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.